Nefazodone in the Treatment of Social Phobia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Completion Date

2000-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the effectiveness of nefazadone in patients with social anxiety disorder (SAD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Vilazodone to Treat Social Anxiety Disorder

NCT01712321

Social Anxiety Disorder

UNKNOWN NA

Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome

NCT00114127

Anxiety Disorder

COMPLETED PHASE3

Geodon for the Treatment of Refractory Social Anxiety Disorder

NCT00215150

Social Anxiety Disorder

COMPLETED PHASE2

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

NCT05193409

Social Anxiety Disorder

COMPLETED PHASE2

Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia

NCT00515879

Social Anxiety Disorder

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to examine the efficacy of the 5HT2 receptor antagonist nefazadone in SAD, and to explore regional cerebral blood flow in patients with SAD when confronted with a personal phobic stimulus, using positron emission tomography (PET). Changes in cerebral blood flow were correlated with self-rated anxiety measures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Social Anxiety Disorder (SAD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nefazodone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DSM-IV diagnosis of generalized social anxiety disorder, males and females between the ages of 18-65

Exclusion Criteria

* A history of bipolar disorder, psychotic illness, or any other anxiety disorders, organic brain disease or active drug or alcohol abuse within one year as assessed by the SCID-P and interview, or a concurrent medical condition that would not be compatible with the study in the opinion of the principal investigator. Patients required to be free of psychotropic or beta-blocker medication for 2 weeks prior to study. Pts taking fluoxetine required to be drug-free for 6 weeks.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes